A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer
Interventions: DRUG: ARX788|DRUG: Pyrotinib maleate|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Docetaxel|DRUG: Carboplatin
Sponsor: Caigang Liu
Collaborators: Jiangsu HengRui Medicine Co., Ltd.